A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)
Clinical trial NCT04721977 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04721977
- Sponsor
- Pfizer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-04-08
- Primary completion
- 2023-07-17
- Enrollment
- 66
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.